SEDA Pharmaceutical Development Services provide Pharmaceutical Development and Clinical Pharmacology services to the Pharma and Biotechnology Industries. We rapidly and efficiently develop medicinal products by providing coherent and synergistic services across four key areas not usually found in one organisation: Chemistry Manufacturing and Controls (CMC) – Product Development; Clinical Pharmacology and Biopharmaceutics; Drug Delivery System Scouting; Biotechnology Investment Support Services. Our philosophy is to transform the value of our clients’ assets by genuinely integrating the clinical and pharmaceutical development needs for the product at the start and throughout the design process thus leading to rapid and efficient development: reducing false starts and ensuring the product meets the patient’s needs. Additionally we will invest in modelling and simulation tools alongside, miniaturization, manufacturing innovations and automation to further increase our ability to take products rapidly into clinical trials and towards commercialisation. Our core technology areas include: Standard oral IR products; Enhanced formulations for poorly, soluble drugs; Complex parenterals;• Inhaled dosage forms. We have applied our knowledge across several therapeutic areas and importantly have extensive experience in the development of Oncology drugs. This includes those with ‘breakthrough status’ which puts particular pressure on the CMC and clinical pharmacology elements of drug development. We are made up of senior ex- big pharma professionals who are experienced across the entire product development timeline from pre-clinical development through to launch and have led development activities for several successful drugs. Additionally we are thought leaders at the forefront of recent scientific and technical developments in the pharmaceutical sciences where we have played leading roles in a number of high profile cross-industry collaborations.